Literature DB >> 10911990

Myotonic dystrophy: the role of the CUG triplet repeats in splicing of a novel DMPK exon and altered cytoplasmic DMPK mRNA isoform ratios.

G Tiscornia1, M S Mahadevan.   

Abstract

The mechanism by which (CTG)n expansion in the 3' UTR of the DMPK gene causes myotonic dystrophy (DM) is unknown. We identified four RNA splicing factors--hnRNP C, U2AF (U2 auxiliary factor), PTB (polypyrimidine tract binding protein), and PSF (PTB associated splicing factor)--that bind to two short regions 3' of the (CUG)n, and found a novel 3' DMPK exon resulting in an mRNA lacking the repeats. We propose that the (CUG)n is an essential cis acting element for this splicing event. In contrast to (CUG)n containing mRNAs, the novel isoform is not retained in the nucleus in DM cells, resulting in imbalances in relative levels of cytoplasmic DMPK mRNA isoforms and a new dominant effect of the mutation on DMPK.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10911990     DOI: 10.1016/s1097-2765(00)80261-0

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  23 in total

1.  Selective silencing of mutated mRNAs in DM1 by using modified hU7-snRNAs.

Authors:  Virginie François; Arnaud F Klein; Cyriaque Beley; Arnaud Jollet; Camille Lemercier; Luis Garcia; Denis Furling
Journal:  Nat Struct Mol Biol       Date:  2010-12-26       Impact factor: 15.369

2.  In vivo co-localisation of MBNL protein with DMPK expanded-repeat transcripts.

Authors:  M Fardaei; K Larkin; J D Brook; M G Hamshere
Journal:  Nucleic Acids Res       Date:  2001-07-01       Impact factor: 16.971

3.  Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy.

Authors:  Susan A M Mulders; Walther J A A van den Broek; Thurman M Wheeler; Huib J E Croes; Petra van Kuik-Romeijn; Sjef J de Kimpe; Denis Furling; Gerard J Platenburg; Geneviève Gourdon; Charles A Thornton; Bé Wieringa; Derick G Wansink
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-10       Impact factor: 11.205

4.  High-throughput analysis of human cytomegalovirus genome diversity highlights the widespread occurrence of gene-disrupting mutations and pervasive recombination.

Authors:  Steven Sijmons; Kim Thys; Mirabeau Mbong Ngwese; Ellen Van Damme; Jan Dvorak; Marnix Van Loock; Guangdi Li; Ruth Tachezy; Laurent Busson; Jeroen Aerssens; Marc Van Ranst; Piet Maes
Journal:  J Virol       Date:  2015-05-13       Impact factor: 5.103

5.  Consensus PP1 binding motifs regulate transcriptional corepression and alternative RNA splicing activities of the steroid receptor coregulators, p54nrb and PSF.

Authors:  Liangliang Liu; Ning Xie; Paul Rennie; John R G Challis; Martin Gleave; Stephen J Lye; Xuesen Dong
Journal:  Mol Endocrinol       Date:  2011-05-12

6.  Gene targeting by the vitamin D response element binding protein reveals a role for vitamin D in osteoblast mTOR signaling.

Authors:  Thomas S Lisse; Ting Liu; Martin Irmler; Johannes Beckers; Hong Chen; John S Adams; Martin Hewison
Journal:  FASEB J       Date:  2010-12-01       Impact factor: 5.191

7.  PSF is a novel corepressor that mediates its effect through Sin3A and the DNA binding domain of nuclear hormone receptors.

Authors:  M Mathur; P W Tucker; H H Samuels
Journal:  Mol Cell Biol       Date:  2001-04       Impact factor: 4.272

Review 8.  Misregulation of alternative splicing causes pathogenesis in myotonic dystrophy.

Authors:  N Muge Kuyumcu-Martinez; Thomas A Cooper
Journal:  Prog Mol Subcell Biol       Date:  2006

9.  Alternative splicing controls myotonic dystrophy protein kinase structure, enzymatic activity, and subcellular localization.

Authors:  Derick G Wansink; René E M A van Herpen; Marga M Coerwinkel-Driessen; Patricia J T A Groenen; Brian A Hemmings; Bé Wieringa
Journal:  Mol Cell Biol       Date:  2003-08       Impact factor: 4.272

10.  Molecular Effects of the CTG Repeats in Mutant Dystrophia Myotonica Protein Kinase Gene.

Authors:  Beatriz Llamusí; Ruben Artero
Journal:  Curr Genomics       Date:  2008-12       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.